HCV + PWID-Yale University-Hepatitis C

HCV + PWID-Yale University-Hepatitis C refers to the therapeutic intervention arm of the TLC-IDU Kenya clinical trial (Testing and Linkage to Care for Injecting Drug Users in Kenya), led by **Yale University**. This intervention involves the administration of direct-acting antiviral (DAA) regimens, specifically **sofosbuvir-based** combinations, to people who inject drugs (PWID) who are infected with the Hepatitis C virus (HCV). The treatment is delivered via Directly Observed Therapy (DOT) for 84 consecutive days. The study evaluates the efficacy of these regimens and the impact of integrated care models (including peer case management and medication-assisted treatment clinics) on treatment adherence and viral clearance in a high-risk population in sub-Saharan Africa.

Other names

Sofosbuvir-based regimensDirect-acting antiviral regimens for PWIDTLC-IDU Kenya HCV Treatment